or investors in Clovis Oncology (CLVS), this may be a case of “Better late, than never.”

Two years after an R&D expert publicly questioned the veracity of clinical trial data released by the drug maker, Clovis executives disclosed that the Securities and Exchange Commission may pursue a civil enforcement action or administrative proceeding against the company.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.